Prognostic Model for MASLD Related Cirrhosis

This study enrolled 228 patients with MASLD-related cirrhosis confirmed by histopathology or clinical diagnosis. Follow-up was conducted every 3-6 months. The primary endpoint was cumulative incidence of liver-related events (including decompensation events, hepatocellular carcinoma, liver transplantation, and liver-related mortality) and all-cause mortality. Secondary endpoints included cumulative incidence of metabolic events and changes in non-invasive fibrosis markers.

NCT Number	NCT07082751
Lead Sponsor	Beijing Friendship Hospital
Conditions	Metabolic Dysfunction Associated Steatotic Liver Disease, Compensated Cirrhosis
Enrollment	228 participants
Start Date	2025-08-13
Primary Completion	2030-06-30 (estimated)
Study Completion	2030-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-07-24